Inflammation and neurodegenerative disorders: Is there still hope for therapeutic intervention?

Current Opinion in Psychiatry

Volumn 28, Issue 2, 2015, Pages 148-154

  Baune, Bernhard T ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Anti inflammation; immune modulation; inflammation; intervention; neurodegeneration

Indexed keywords

ANTIINFLAMMATORY AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; INFLAMMASOME;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CLINICAL EVALUATION; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; INTERVENTION STUDY; NERVE DEGENERATION; NERVOUS SYSTEM; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; THERAPY EFFECT; INFLAMMATION; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY;

HUMANS; INFLAMMASOMES; INFLAMMATION; NEURODEGENERATIVE DISEASES;

EID: 84922401185     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000140     Document Type: Review

References (100)

1. Heneka] MT, O'Banion MK, Terwel D, Kummer MP. Neuroinflammatory processes in Alzheimer's disease. J Neural Transmission 2010; 117:919-947.
2. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 2012; 18:S210-S212.
3. Godbout JP, Moreau M, Lestage J, et al. Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system. Neuropsychopharmacology 2008; 33:2341-2351.
4. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013; 18:595-606.
5. Huang Y, Henry C, Dantzer R, et al. Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide. Neurobiol Aging 2008; 29:1744-1753.
6. Mrak RE, Griffin WST. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005; 26:349-354.
7. Dilger RN, Johnson RW. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukocyte Biol 2008; 84:932-939.
8. Sugaya K, Chouinard M, Greene R, et al. Molecular indices of neuronal and glial plasticity in the hippocampal formation in a rodent model of age-induced spatial learning impairment. J Neurosci 1996; 16:3427-3443.
9. Rozovsky I, Finch C, Morgan T. Age-related activation of microglia and astrocytes: in vitro studies show persistent phenotypes of aging, increased proliferation, and resistance to down-regulation. Neurobiol Aging 1998; 19:97-103.
10. Streit WJ. Microglia and neuroprotection: implications for Alzheimer's disease. Brain Res Rev 2005; 48:234-239.
11. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001; 36:180-190.
12. Auriel E, Regev K, Korczyn AD. Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. Handbook Clin Neurol 2014; 119:577-584.
13. Hannestad J, Della Gioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011; 36:2452-2459.
14. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67:446-457.
15. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009; 71:171-186.
16. Maes M, Bosmans E, De Jongh R, et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9:853-858.
17. Farooq RK, Isingrini E, Tanti A, et al. Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation Behav Brain Res 2012; 231:130-137.
18. Zhang Y, Liu L, Peng YL, et al. Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neurosci Therap 2014; 20:119-124.
19. Alcocer-Gómez E, de Miguel M, Casas-Barquero N, et al. NLRP3 inflammasome is activated in mononuclear blood cells from pateints with major depressive disorder. Brain Behav Immun 2014; 36:111-117.
20. Hohmann H, Bechter K, Schneider E. A small and validated cytokine panel supports inflammasome activation in cerebrospinal fluid of patients with major depression and schizophrenia. Neurol Psychiatry Brain Res 2014; 20:13-14.
21. Moon M, McCusker R, Lawson M, et al. Mice lacking the inflammasome component caspase-1 are resistant to central lipopolysaccharide-induced depressive-like behavior. Brain Behav Immun 2009; 23:S50.
22. Kamboh M, Demirci F, Wang X, et al. Genome-wide association study of Alzheimer's disease. Transl Psychiatry 2012; 2:e117.
23. Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer's disease. Hum Mol Genet 2009; 18:R137-R145.
24. Babic T. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 67:558.
25. Palop JJ, Mucke L. Amyloid-[beta]-induced neuronal dysfunction in Alzheimer's disease: fromsynapses toward neural networks. NatNeurosci 2010; 13:812-818.
26. Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8:663-672.
27. Agostinho P, A Cunha R, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharmaceut Des 2010; 16:2766-2778.
28. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987; 79:195-200.
29. Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exper Neurol 1996; 55:1083-1088.
30. Lynch MA, Mills KH. Immunology meets neuroscience-opportunities for immune intervention in neurodegenerative diseases. Brain Behav Immun 2012; 26:1-10.
31. Hein AM, O'Banion MK. Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol 2009; 40:15-32.
32. Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res 2010; 88:1615-1631.
33. Laye S. Polyunsaturated fatty acids, neuroinflammation and well being. Prostaglandins Leukot Essent Fatty Acids 2010; 82:295-303.
34. Maccioni RB, Rojo LE, Fernandez JA, Kuljis RO. The role of neuroimmunomodulation in Alzheimer's disease. Ann N Y Acad Sci 2009; 1153:240-246.
35. Farooqui T, Farooqui AA. Aging: an important factor for the pathogenesis of neurodegenerative diseases. Mech Ageing Dev 2009; 130:203-215.
36. Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011; 477:90-94.
37. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011; 130:226-238.
38. Wenk GL. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 2003; 64:7-10.
39. Tabet N. Acetylcholinesterase inhibitors for Alzheimer's disease: antiinflammatories in acetylcholine clothing! Age Ageing 2006; 35:336-338.
40. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65:1509-1517.
41. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004; 84:361-384.
42. Lee H-G, Perry G, Moreira PI, et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector Trends Mol Med 2005; 11:164-169.
43. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. Sci World J 2012; 2012; 756357.
44. Liu L, Chan C. The role of inflammasome in Alzheimer's disease. Ageing Res Rev 2014; 15:6-15.
45. Meraz-Rós MA, Toral-Rios D, Franco-Bocanegra D, et al. Inflammatory process in Alzheimer's disease. Front Integr Neurosci 2013; 7:59.
46. Lee JW, Lee YK, Yuk DY, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of betaamyloid generation. J Neuroinflammation 2008; 5:37.
47. Sheng JG, Bora SH, Xu G, et al. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid (peptide in APPswe transgenic mice. Neurobiol Dis 2003; 14:133-145.
48. Kitazawa M, Oddo S, Yamasaki TR, et al. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005; 25:8843-8853.
49. Tan MS, Yu JT, Jiang T, et al. The NLRP3 inflammasome in Alzheimer's disease. Mol Neurobiol 2013; 48:875-882.
50. Marchesi VT. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 2011; 25:5-13.
51. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-b. Nat Immunol 2008; 9:857-865.
52. Freund-Levi Y, Hjorth E, Lindberg C, et al. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia Geriatr Cogn Disord 2009; 27:481-490.
53. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63:1402-1408.
54. Orr SK, Trepanier MO. Bazinet RP. n-3 Polyunsaturated fatty acids in animal models with neuroinflammation. Prostaglandins Leukot Essent Fatty Acids 2013; 88:97-103.
55. Hjorth E, Zhu M, Toro VC, et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-beta42 by human microglia and decrease inflammatory markers. J Alzheimers Dis 2013; 35:697-713.
56. Labrousse VF, Nadjar A, Joffre C, et al. Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PloS One 2012; 7:e36861.
57. Mizwicki MT, Liu G, Fiala M, et al. 1alpha,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-beta phagocytosis and inflammation in Alzheimer's disease patients. J Alzheimers Dis 2013; 34:155-170.
58. Gupta S, Knight AG, Keller JN, Bruce-Keller AJ. Saturated long-chain fatty acids activate inflammatory signaling in astrocytes. J Neurochem 2012; 120:1060-1071.
59. Latour A, Grintal B, Champeil-Potokar G, et al. Omega-3 fatty acids deficiency aggravates glutamatergic synapse and astroglial aging in the rat hippocampal CA1. Aging Cell 2013; 12:76-84.
60. Vedin I, Cederholm T, Freund Levi Y, et al. Effects of docosahexaenoic acidrich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr 2008; 87:1616-1622.
61. Vedin I, Cederholm T, Freund-Levi Y, et al. Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study. J Lipid Res 2010; 51:1179-1185.
62. Vedin I, Cederholm T, Freund-Levi Y, et al. Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PloS One 2012; 7:e35425.
63. Bouwens M, van de Rest O, Dellschaft N, et al. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr 2009; 90:415-424.
64. Faber J, Berkhout M, Vos AP, et al. Supplementation with a fish oil-enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses within one week in healthy men and women. J Nutr 2011; 141:964-970.
65. Nilsson A, Radeborg K, Salo I, Bjorck I. Effects of supplementation with n-3 polyunsaturated fatty acids on cognitive performance and cardiometabolic risk markers in healthy 51 to 72 years old subjects: a randomized controlled cross-over study. Nutr J 2012; 11:99.
66. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26:607-611.
67. Almeida OP, Alfonso H, Jamrozik K, et al. Aspirin use, depression, and cognitive impairment in later life: the health in men study. J Am Geriatr 2010; 58:990-992.
68. Fields C, Drye L, Vaidya V, Lyketsos C. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry 2011; 20:505-513.
69. Gallagher PJ, Castro V, Fava M, et al. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 2012; 169:1065-1072.
70. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a doubleblind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11:680-684.
71. Musil R, Schwarz MJ, Riedel M, et al. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression-no influence of celecoxib treatment. J Affect Disord 2011; 134:217-225.
72. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008; 23:87-94.
73. Pasco JA, Jacka FN, Williams LJ, et al. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 2010; 79:323-325.
74. Uher R, Carver S, Power RA, et al. Nonsteroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychol Med 2012; 42:1-9.
75. Warner-Schmidt JL, Vanover KE, Chen EY, et al. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci USA 2011; 108:9262-9267.
76. Shelton RC. Does concomitant use of NSAIDs reduce the effectiveness of antidepressants Am J Psychiatry 2012; 169:1012-1015.
77. Muller N. The role of anti-inflammatory treatment in psychiatric disorders. Psychiatria Danubina 2013; 25:292-298.
78. Fond G, Hamdani N, Kapczinski F, et al. Effectiveness and tolerance of antiinflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatrica Scand 2013.
79. Almeida OP, Flicker L, Yeap BB, et al. Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl Psychiatry 2012; 2:e151.
80. Maes M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis 2012; 27:405-413.
81. Aid S, Bosetti F. Targeting cyclooxygenases-1 and-2 in neuroinflammation: therapeutic implications. Biochimie 2011; 93:46-51.
82. Berk M, Dean O, Drexhage H, et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 2013; 11:74.
83. Na KS, Lee KJ, Lee JS, et al. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 48C:79-85.
84. Aid S, Langenbach R, Bosetti F. Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation 2008; 5:17.
85. Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and nonsteroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012; 2:CD006378.
86. Terrando N, Monaco C, Ma D, et al. Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci USA 2010; 107:20518-20522.
87. Couch Y, Anthony DC, Dolgov O, et al. Microglial activation, increased TNF and SERT expression in the prefrontal cortex define stress-altered behaviour in mice susceptible to anhedonia. Brain Behav Immun 2013; 29:136-146.
88. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 2008; 5:2.
89. Miller GE, Cole SW. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry 2012; 72:34-40.
90. Camara ML, Corrigan F, Jaehne EJ, et al. Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology 2015; 40:502-512.
91. Baune BT, Wiede F, Braun A, et al. Cognitive dysfunction in mice deficient for TNF-and its receptors. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:1056-1064.
92. Golan H, Levav T, Mendelsohn A, Huleihel M. Involvement of tumor necrosis factor alpha in hippocampal development and function. Cereb Cortex 2004; 14:97-105.
93. Beattie EC, Stellwagen D, Morishita W, et al. Control of synaptic strength by glial TNFalpha. Science 2002; 295:2282-2285.
94. Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factoralpha. J Neurosci 2005; 25:3219-3228.
95. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009; 33:355-366.
96. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160:943-952.
97. Longhi L, Ortolano F, Zanier ER, et al. Effect of traumatic brain injury on cognitive function in mice lacking p55 and p75 tumor necrosis factor receptors. Acta Neurochir Suppl 2008; 102:409-413.
98. Zhu L, Bi W, Lu D, et al. Regulation of ubiquitin-specific processing protease 8 suppresses neuroinflammation. Mol Cell Neurosci 2014; 23:74-83.
99. Zhou W, Yuan J. Necroptosis in health and diseases. Sem Cell Dev Biol 2014; 35:14-23.
100. Vasconcelos AR, Yshii LM, Viel TA, et al. Intermittent fasting attenuates lipopolysaccharide-induced neuroinflammation and memory impairment. J Neuroinflammation 2014; 11:85.